Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Inclusion Criteria

• •1. Patient is male or female and at least 18 years of age.
• •2. Female patients must be of either:
• •* Non-childbearing potential, provided there is a laboratory confirmed serum follicle stimulating hormone (FSH) level ≥ 40mIU/ml or there is a confirmed clinical history of sterility (e.g., the patient is without a uterus); or
• •* Childbearing potential, provided there are negative urine pregnancy test results prior to study treatment, to rule out pregnancy.
• •3. Patient has provided informed consent documented by signing the Informed Consent Form (ICF) prior to any study-related procedures, including any alteration of medications in preparation for study entry.
• •4. Patient has agreed to allow photographs of the selected treatment lesions to be taken and used as part of the study data package.